(Q33404547)

26 July 2017

0 references

Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis (English)

1 reference

metastatic renal cell carcinoma

26 July 2017

1 reference

1 reference

1 reference

Khaled M Abouelkhair

3

0 references

author name string

Ezzeldin M Ibrahim

1

1 reference

26 July 2017

Ghieth A Kazkaz

2

1 reference

26 July 2017

Ali M Bayer

4

1 reference

26 July 2017

Osama A Elmasri

5

1 reference

26 July 2017

publication date

21 November 2012

1 reference

International Journal of Clinical Oncology

26 July 2017

published in

1 reference

26 July 2017

volume

18

1 reference

26 July 2017

issue

6

1 reference

26 July 2017

page(s)

1060-1069

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

26 July 2017

1 reference

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Treatment of metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Methodological index for non-randomized studies (minors): development and validation of a new instrument

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

STrengthening the Reporting of OBservational studies in Epidemiology--Molecular Epidemiology (STROBE-ME): an extension of the STROBE Statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Meta-analysis of mortality and cancer incidence among workers in the synthetic rubber-producing industry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Review: a gentle introduction to imputation of missing values

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Renal cell carcinoma: diagnosis, staging, and surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Sunitinib induces hypothyroidism with a markedly reduced vascularity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Impact of sample size on variation of adverse events and preventable adverse events: systematic review on epidemiology and contributing factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Can administrative data be used to compare postoperative complication rates across hospitals?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0497-2

21 January 2018

1 reference

12 December 2020

The placebo effect in healthy volunteers: influence of experimental conditions on the adverse events profile during phase I studies

1 reference

12 December 2020

Hypothyroidism in patients with renal cell carcinoma: blessing or curse?

1 reference

12 December 2020

A Novel Tyrosine-Kinase Selective Inhibitor, Sunitinib, Induces Transient Hypothyroidism by Blocking Iodine Uptake

1 reference

12 December 2020

Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma

1 reference

12 December 2020

Adverse events: the more you search, the more you find

1 reference

12 December 2020

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

12 December 2020

10.1007/S10147-012-0497-2

Identifiers

DOI

1 reference

26 July 2017

1 reference